NEW DATA SHOWS AMGEN’S REPATHA LOWERS HEART ATTACK RISK, BUT ANOTHER STUDY FOUND HIGH REJECTION RATES BY INSURERS.
Cost-Benefit Quest
Monday, April 3, 2017
In a tale of two studies, health researchers report that Amgen Inc...
Take 1 minute to subscribe and you'll get this story immediately, plus:
Already a subscriber? Sign in
- 26 biweekly issues
- Subscriber-only digital content for prime stories
- Book of Lists — the most comprehensive business resource in the Valley region